Cycle™ Pharmaceuticals, a pioneering pharmaceuticals company based in Cambridge, has appointed KISS Communications to act as its healthcare communications agency.

Man kissing little boys head

The first project briefed to KISS was the launch of NITYR™ (nitisinone) tablets a drug to treat patients with an ultra-rare disease called Hereditary Tyrosinaemia type 1 (HT-1), in the U.S. market. As Sarah Reakes, Managing Director of KISS, comments, the project required an entirely integrated approach.

“In launching NITYR we created a brand language and a full suite of specialised marketing collateral from brochures and presentations to a mobile responsive website in a matter of weeks. We also worked closely with our PROI partner agency, rbb Communications, in the U.S to develop the Americanised copy required for all these elements, as well as a launch to U.S. media."

“We are delighted to have been appointed by Cycle, a company working on some incredible innovations and a strong pipeline within the pharmaceutical industry.”

Paula Bekinschtein, Global Marketing Manager at Cycle Pharmaceuticals says: “This project was delivered in full in just six weeks, which is testament to the talented pool of professionals and the multi-disciplinary skill set within KISS. It was a big ask and their rapid response was exceptional without any compromise on the quality of their work - which is exactly what is needed within such a specialised healthcare sector as ours.”

For full prescribing information please visit: www.nityr.us/PI